TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO)
- Previous Close
7.93 - Open
7.93 - Bid --
- Ask --
- Day's Range
7.66 - 7.93 - 52 Week Range
6.99 - 13.05 - Volume
21,631 - Avg. Volume
84,717 - Market Cap (intraday)
635.368M - Beta (5Y Monthly) -1.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.29 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.
www.taiwanj.comRecent News: 6549.TWO
View MorePerformance Overview: 6549.TWO
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6549.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6549.TWO
View MoreValuation Measures
Market Cap
632.96M
Enterprise Value
545.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.66
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.33%
Return on Equity (ttm)
-27.58%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-22.34M
Diluted EPS (ttm)
-0.29
Balance Sheet and Cash Flow
Total Cash (mrq)
87.61M
Total Debt/Equity (mrq)
0.50%
Levered Free Cash Flow (ttm)
-15.04M